olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide · OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 · Tablet, Film Coated · Oral · Slate Run Pharmaceuticals, LLC
NDC 70436-0015-04 · 30 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. Put together: worth watching — several of the pressures that precede supply trouble are present at once.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 20 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 5 mg/1; AMLODIPINE BESYLATE 25 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 10 mg/1; AMLODIPINE BESYLATE 12.5 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 10 mg/1; AMLODIPINE BESYLATE 25 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 5 mg/1; AMLODIPINE BESYLATE 12.5 mg/1; HYDROCHLOROTHIAZIDE 20 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 5 mg/1; AMLODIPINE BESYLATE 12.5 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Slate Run Pharmaceuticals, LLC | AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Slate Run Pharmaceuticals, LLC | AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Slate Run Pharmaceuticals, LLC | AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Slate Run Pharmaceuticals, LLC | AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Slate Run Pharmaceuticals, LLC | AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide — NDC 70436-0015-04," retrieved September 3, 2026, https://drugdashboards.com/drug/70436001504.
Free to cite with attribution — see how the data is put together.